Loading stock data…
$1.04-0.03 (-2.34%)
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Coherus Oncology, Inc. in the Healthcare sector is trading at $1.04 with a market capitalization of $219M. Wall Street consensus targets $7.75 (4 analysts), implying a +641.6% move over the next 12 months. The stock is currently near its 52-week low of $0.97, remaining 33.0% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.31M↑ | $12.31M↓ | $12.75M↑ | $11.57M↑ | $10.25M |
| Gross Profit | $10.06M↑ | $8.50M↓ | $8.70M↑ | $7.85M↑ | $6.86M |
| Operating Income | -$32.33M↑ | -$36.15M↑ | -$45.88M↓ | -$44.33M↑ | -$45.49M |
| Net Income | -$20.63M↑ | -$38.33M↓ | -$37.64M↓ | -$35.53M↓ | $297.77M |
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating f...